The Latest Analyst Ratings For Globus Medical
Portfolio Pulse from Benzinga Insights
Analyst ratings for Globus Medical (NYSE:GMED) show a diverse range of opinions, with recent updates indicating a generally positive outlook. Over the past quarter, 6 analysts have provided ratings, with the latest 12-month price targets suggesting an average increase of 6.83% to $63.83. Recent analyst actions include upgrades and maintenance of buy and hold ratings, reflecting changes in market dynamics and company performance. Globus Medical, a medical device company, has shown significant revenue growth of 124.6% as of December 31, 2023, but faces challenges in net margin, ROE, and ROA, indicating potential areas for improvement in profitability and asset management.
March 18, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Globus Medical has received positive analyst ratings with an updated average 12-month price target of $63.83, indicating a potential upside. The company has demonstrated substantial revenue growth but faces challenges in profitability metrics.
The positive analyst ratings and increased price targets suggest confidence in Globus Medical's growth prospects, likely driving short-term investor optimism. However, the noted challenges in profitability and asset management metrics could temper long-term expectations, making the short-term impact more pronounced.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100